

Mar. 31, 2011

The License Agreement of the Transdermal Formulation containing NF- κ B Decoy Oligonucleotide has been signed with AnGes MG Inc.

MEDRx Co. Ltd. (MEDRx) promotes R&D of the transdermal formulations to extremely enhance skin permeability of high molecular drug candidates such as nucleic acid and peptide by its unique transdermal formulation technologies, ILTS® (Ionic Liquid Transdermal System), compared with the conventional transdermal technologies.

MEDRx has been developing the new formulation to improve the skin permeability of NF- κ B Decoy Oligonucleotide using its ILTS® technologies with AnGes MG Inc. (AnGes). MEDRx announces that MEDRx granted the license related to the transdermal formulation containing NF- κ B Decoy Oligonucleotide to AnGes. AnGes is developing NF- κ B Decoy Oligonucleotide as an ethical drug for skin disease treatment such as atopic dermatitis.

FOR DETAILS, SEND E-mail at info@medrx.co.jp

